ArticleCurrent neuropharmacology2012
Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review.
Article in Current neuropharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 120 citations in OpenAlex.
- Assessing the Labeling Information on Drugs Associated With Suicide Risk: Systematic Review.JMIR public health and surveillance · 2024Pooled it
- Pooled it
- Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.The international journal of neuropsychopharmacology · 2015Pooled it
- Cariprazine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder: A case report.Biomedical reports · 2026Article
- Pharmacological Intensification Strategies in Highly Refractory Obsessive-Compulsive Disorder: Evidence Synthesis and a Tertiary-Care Case Series.Journal of clinical medicine · 2026Review
- Transitioning from clozapine to Cobenfy (xanomeline-trospium chloride) in treatment resistant schizophrenia and clozapine induced OCD.BMC psychiatry · 2026Article
- Negative symptomatology and clozapine-induced obsessive-compulsive symptoms: a cross-sectional analysis.European archives of psychiatry and clinical neuroscience · 2026Article
- Clozapine-induced obsessive-compulsive symptoms in schizophrenia: Clinical and cognitive determinants of dysfunctional checking.Psychological medicine · 2025Article
- Obsessive‒compulsive symptoms and associated factors among people with schizophrenia attending services at referral hospitals in Eastern Ethiopia.BMC psychiatry · 2025Article
- The relationship between obsessive-compulsive symptoms and real-life functioning in schizophrenia: New insights from the multicenter study of the Italian Network for Research on Psychoses.European psychiatry : the journal of the Association of European Psychiatrists · 2024Article
- Polygenetic risk scores and phenotypic constellations of obsessive-compulsive disorder in clozapine-treated schizophrenia.European archives of psychiatry and clinical neuroscience · 2024Article
- The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia.Biomolecules · 2023Review
- Clozapine-Induced Obsessive-Compulsive Symptoms and Augmentation with Clonazepam: Risks and Rationales.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2023Article
- De Novo Seizures, Obsessive Compulsive Symptoms and Neutropenias in Patients on Clozapine: A Retrospective Cohort Study.Indian journal of psychological medicine · 2023Article
- Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia.Therapeutic advances in psychopharmacology · 2023Review
- Pivotal mental states.Journal of psychopharmacology (Oxford, England) · 2021Review
- Pharmacotherapeutic Strategies and New Targets in OCD.Current topics in behavioral neurosciences · 2021Review
- Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapine.European archives of psychiatry and clinical neuroscience · 2019Article
- A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2019Article
- Clozapine-induced obsessive–compulsive symptoms: mechanisms and treatmentJournal of psychiatry & neuroscience : JPN · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obsessive-compulsive disorder (OCD) is rarely associated with schizophrenia, whereas 20 to 30% of schizophrenic patients, suffer from comorbid obsessive-compulsive symptoms (OCS). So far no single pathogenetic theory convincingly explained this fact suggesting heterogeneous subgroups. Based on long-term case observations, one hypothesis assumes that second-onset OCS in the course of schizophrenia might be a side effect of second generation antipsychotics (SGA), most importantly clozapine (CLZ). This review summarizes the supporting epidemiological and pharmacological evidence: Estimations on prevalence of OCS increase in more recent cross-sectional studies and in later disease stages. Longitudinal observations report the de novo-onset of OCS under clozapine treatment. This association has not been reported with first generation antipsychotics (FGA) or SGAs with mainly dopaminergic mode of action. Finally, significant correlations of OCS-severity with duration of treatment, dose and serum levels suggest clozapine-induced OCS. However, supposed causal interactions need further verifications. It is also unclear, which neurobiological mechanisms might underlie the pathogenetic process. Detailed genotypic and phenotypic characterizations of schizophrenics with comorbid OCS regarding neurocognitive functioning and activation in sensitive tasks of functional magnetic imaging are needed. Multimodal large-scaled prospective studies are necessary to define patients at risk for second-onset OCS and to improve early detection and therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.